Tablets
5 Billion per Annum
BioMatrix’s manufacturing facility is equipped with the latest and the best of equipments, technology and manpower. Having the coveted WHO-GMP and EU-GMP approval, the unit is also compliant with USFDA, UK-MHRA, and ANVISA standards. Located at Ahmedabad, India, the plant has captive and buffer capacities which can meet the future demands, keeping in mind the company’s ambitious growth and expansion plans. Likewise, the design and installed machinery are also futuristic, and are on par with any global manufacturing setup.
The scope and scale of our manufacturing unit help us to provide safe, affordable, and effective medicines globally.
Our manufacturing unit specializes in the production of:
We are thrilled to announce that our Oral Solids, Liquids and Dry syrup facility has received EUGMP approval! This achievement is a testament to unwavering dedication and commitment of our Team.
Read more
It was a phenomenal experience for BioMatrix to be a part of Iphex 2024 and to interact with multiple international delegates to explore collaboration opportunities for improved healthcare. IPHEX, organised by PHARMEXCIL is one of the largest exhibitions showcasing Indian pharmaceutical products and technologies to a global audience.
Read more
We had a great time attending and exhibiting at CPHI Worldwide in Milan. It’s been an amazing three days of networking, learning and growth. A huge thank you to everyone who visited us and to our dedicated team for their tireless efforts that made all of this possible. We’re excited about the future collaborations and innovations ahead. Stay connected with us for more updates and exciting projects.
Read more
Exciting Milestone Achieved! We’re thrilled to share that BioMatrix Healthcare Pvt. Ltd. has received site approval from Health Canada! A big kudos to our incredible team for their unwavering dedication and expertise. This milestone reflects our commitment to quality and innovation in healthcare! Here’s to many more milestones ahead!.
Read more
BioMatrix had an incredible experience at Iphex 2025, engaging with international delegates and exploring impactful collaborations for a healthier future. This year’s participation gave us the opportunity to strengthen global connections, showcase our commitment to quality healthcare, and open new doors for partnerships across continents.
Read more
We proudly announce a regulatory milestone with site approval from the Food and Drug Administration (FDA), Philippines.This approval reflects our continued commitment to maintaining global quality standards and ensuring the safety and efficacy of our products.
Read more
We are pleased to announce the successful approval from the Iraqi Ministry of Health, marking another important step in our global regulatory expansion. This achievement strengthens our presence in the Middle East and reflects our commitment to meeting international quality and regulatory standards.
Read more
BioMatrix Healthcare marked a strong presence at CPHI Frankfurt 2025, engaging with global leaders and collaborators to drive innovation and excellence in pharmaceuticals.
Read more
We are proud to announce the approval of our first European Market Authorization (MA) for Sitagliptin Tablets (25 mg, 50 mg & 100 mg). This achievement marks a major step forward in our global expansion journey and reflects the hard work, dedication, and excellence of our entire team.
Read more